An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation

Oncogene

Volumn 33, Issue 33, 2014, Pages 4273-4278

  Wolf, J ^a   Muller Decker K ^a   Flechtenmacher, C ^b   Zhang, F ^c   Shahmoradgoli, M ^c   Mills, G B ^c   Hoheisel, J D ^a   Boettcher, M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CDH1; EMT; In vivo RNAi screening; SALL1; shRNA screen; tumor suppressor

Indexed keywords

ACIDIC (LEUCIN-RICH) NUCLEAR PHOSPHOPROTEIN 32 FAMILY; ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE MONOPHOSPHATE DEAMINASE 1; CALPAIN 1; CASPASE 8; DNA GLYCOSYLASE MUTY; DOLICHYL PHOSPHATE MANNOSYLTRANSFERASE POLYPEPTIDE 1; EGF LIKE MODULE CONTAINING MUCIN LIKE HORMONE RECEPTOR LIKE 3; EPITHELIAL CELL ADHESION MOLECULE; GROWTH DIFFERENTIATION FACTOR 6; GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 14; HERMES ANTIGEN; MANNOSYLTRANSFERASE; MEMBRANE PROTEIN; MESSENGER RNA; PHOSPHOMANNOMUTASE; PHOSPHOMANNOMUTASE 1; PHOSPHOPROTEIN; RAD54 PROTEIN; RAD54L PROTEIN; RETINOIC ACID RECEPTOR GAMMA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SOLUTE CARRIER FAMILY 1 MEMBER 4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR SALL1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CANCER PATIENT; CANCER STEM CELL; CARCINOGENICITY; CELL MIGRATION; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC IDENTIFICATION; GENETIC SCREENING; GENETIC TRANSDUCTION; HOST CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NOD SCID MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION REGULATION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; WESTERN BLOTTING; XENOTRANSPLANTATION;

MUS;

ANIMALS; BREAST NEOPLASMS; CADHERINS; CARCINOGENESIS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84906280767     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.515     Document Type: Article

References (35)

1. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
2. Krelin Y, Berkovich L, Amit M, Gil Z. Association between tumorigenic potential and the fate of cancer cells in a syngeneic melanoma model. PLoS One 2013; 8: e62124.
3. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B et al. An oncogenomicsbased in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008; 135: 852-864.
4. Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 2009; 16: 324-335.
5. de Celis JF, Barrio R. Regulation and function of Spalt proteins during animal development. Int J Dev Biol 2009; 53: 1385-1398.
6. Kohlhase J. SALL1 mutations in Townes-Brocks syndrome and related disorders. Hum Mutat 2000; 16: 460-466. (Pubitemid 32001294)
7. Kiefer SM, Robbins L, Stumpff KM, Lin C, Ma L, Rauchman M. Sall1-dependent signals affect Wnt signaling and ureter tip fate to initiate kidney development. Development 2010; 137: 3099-3106.
8. Karantzali E, Lekakis V, Ioannou M, Hadjimichael C, Papamatheakis J, Kretsovali A. Sall1 regulates embryonic stem cell differentiation in association with nanog. J Biol Chem 2011; 286: 1037-1045.
9. Hill VK, Hesson LB, Dansranjavin T, Dallol A, Bieche I, Vacher S et al. Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer 2010; 9: 51.
10. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-981.
11. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009; 119: 1417-1419.
12. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 2011; 13: 202.
13. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010; 12: 982-992.
14. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715. (Pubitemid 351636299)
15. Cellecta, http://www.decipherproject.net/ 2012.
16. Netzer C, Rieger L, Brero A, Zhang CD, Hinzke M, Kohlhase J et al. SALL1, the gene mutated in Townes-Brocks syndrome, encodes a transcriptional repressor which interacts with TRF1/PIN2 and localizes to pericentromeric heterochromatin. Hum Mol Genet 2001; 10: 3017-3024. (Pubitemid 34083488)
17. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
18. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
19. Wang CC, Liau JY, Lu YS, Chen JW, Yao YT, Lien HC. Differential expression of moesin in breast cancers and its implication in epithelial-mesenchymal transition. Histopathology 2012; 61: 78-87.
20. Haynes J, Srivastava J, Madson N, Wittmann T, Barber DL. Dynamic actin remodeling during epithelial-mesenchymal transition depends on increased moesin expression. Mol Biol Cell 2011; 22: 4750-4764.
21. Chien W, O'Kelly J, Lu D, Leiter A, Sohn J, Yin D et al. Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol 2011; 38: 1741-1747.
22. Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 2002; 21: 8178-8185. (Pubitemid 35454421)
23. Jing C, El-Ghany MA, Beesley C, Foster CS, Rudland PS, Smith P et al. Tazaroteneinduced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J Natl Cancer Inst 2002; 94: 482-490. (Pubitemid 34411286)
24. Hsu TH, Chu CC, Jiang SY, Hung MW, Ni WC, Lin HE et al. Expression of the class II tumor suppressor gene RIG1 is directly regulated by p53 tumor suppressor in cancer cell lines. FEBS Lett 2012; 586: 1287-1293.
25. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011; 146: 633-644.
26. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
27. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005; 7: R953-R964.
28. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010; 107: 10208-10213.
29. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874. (Pubitemid 32878711)
30. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011; 64: 937-946.
31. Argos M, Kibriya MG, Jasmine F, Olopade OI, Su T, Hibshoosh H et al. Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays. Cancer Genet Cytogenet 2008; 182: 69-74. (Pubitemid 351491323)
32. Chin SF, Wang Y, Thorne NP, Teschendorff AE, Pinder SE, Vias M et al. Using arraycomparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 2007; 26: 1959-1970. (Pubitemid 46474632)
33. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008; 68: 3645-3654.
34. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-659.
35. Fredebohm J, Wolf J, Hoheisel JD, Boettcher M. Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine. J Cell Sci 2013; 126: 3380-3389.